UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported) ~~December 26~~ March 11, ~~2013~~ 2014

HI-TECH PHARMACAL CO., INC.

HI-TECH PHARMACAL CO., INC.
(Exact Name of Registrant as Specified in Its Charter)

Delaware
(State or Other Jurisdiction of Incorporation)

No. 0-20424	11-2638720
(Commission File Number)	(IRS Employer Identification No.)

369 Bayview Avenue, Amityville, New York	11701
(Address of Principal Executive Offices)	(Zip Code)

(631) 789-8228
(Registrant’s Telephone Number, Including Area Code)


(Former Name or Former Address, if Changed Since Last Report)

(Exact Name of Registrant as Specified in Its Charter)

Delaware

(State or Other Jurisdiction of Incorporation)

No. 0-20424	11-2638720
(Commission File Number)	(IRS Employer Identification No.)

369 Bayview Avenue, Amityville, New York	11701
(Address of Principal Executive Offices)	(Zip Code)

(631) 789-8228

(Registrant’s Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 82.0102. ~~Other~~Results ~~Events~~of Operations and Financial Condition.

On March 11, 2014 Hi-Tech Pharmacal Co., Inc. ( the “Company”) ~~announced~~issued ~~that~~a ~~the~~press ~~Texas~~release ~~Attorney~~announcing ~~General has agreed to close~~ its ~~investigation~~financial ofresults ~~the~~for ~~Company’s pricing of products that were purchased with Texas Medicaid dollars. In settlement,~~ the ~~Company~~third ~~agreed~~fiscal toquarter ~~pay~~ended ~~$25,000,000~~January ~~to the State of Texas. This amount had previously been accrued in the Company’s financial statements. The settlement does not constitute an admission~~31, ~~finding or evidence of any liability or wrongdoing by the Company~~2014. ~~A copy of the press release is attached as Exhibit 99.1 to this current report and is incorporated herein by reference.~~

A copy of the press release is attached as Exhibit 99.1 to this current report and is incorporated herein by reference.

The information in Item 2.02 and Item 9.01 shall be deemed to be furnished to the Securities and Exchange Commission but not filed and shall not be deemed incorporated by reference into any filings by the Company under the Securities Act of 1933, as amended, unless the Company expressly states otherwise in such filing.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits

The following exhibit is furnished herewith:

Exhibit Number Description

Exhibit Number		Description
Exhibit 99.1		Press Release of Hi-Tech Pharmacal Co., Inc.
		dated March 11, 2014

Exhibit 99.1 Press Release of Hi-Tech Pharmacal Co., Inc. dated December 26, 2013

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 26, 2013	HI-TECH PHARMACAL CO., INC.
Date: March 11, 2014	HI-TECH PHARMACAL CO., INC.
	/s/David S. Seltzer
	/s/ William Peters
	Name: David S. Seltzer
	Name: William Peters
	Title: President and Chief Executive Officer
	Title: Executive Vice President and Chief Financial Officer

INDEX TO EXHIBITS

Exhibit Number	~~Description~~	Description
99.1	~~Press Release of Hi-Tech Pharmacal Co., Inc. dated December 26, 2013~~	Press Release of Hi-Tech Pharmacal Co., Inc. dated March 11, 2014

Filing Compare · HI TECH PHARMACAL CO INC